BR112022010277A2 - Terapia combinada que envolve compostos macrocíclicos de diarila - Google Patents

Terapia combinada que envolve compostos macrocíclicos de diarila

Info

Publication number
BR112022010277A2
BR112022010277A2 BR112022010277A BR112022010277A BR112022010277A2 BR 112022010277 A2 BR112022010277 A2 BR 112022010277A2 BR 112022010277 A BR112022010277 A BR 112022010277A BR 112022010277 A BR112022010277 A BR 112022010277A BR 112022010277 A2 BR112022010277 A2 BR 112022010277A2
Authority
BR
Brazil
Prior art keywords
diaril
macrocyclic
compounds
combined therapy
therapy involving
Prior art date
Application number
BR112022010277A
Other languages
English (en)
Inventor
Deng Wei
Zhai Dayong
Rodon Laura
W Murray Brion
J Cui Jingrong
V Lee Nathan
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of BR112022010277A2 publication Critical patent/BR112022010277A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A presente revelação está relacionada aos métodos e às composições para o tratamento de câncer com um macrociclo de diarila em combinação com um inibidor de MAPK/ERK quinase-1 e -2 (MEK1 e MEK2; MAP2K1 e MAP2K2), por exemplo, trametinib.
BR112022010277A 2019-11-27 2020-11-25 Terapia combinada que envolve compostos macrocíclicos de diarila BR112022010277A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962941031P 2019-11-27 2019-11-27
US201962941033P 2019-11-27 2019-11-27
US202062992573P 2020-03-20 2020-03-20
PCT/US2020/062374 WO2021108672A1 (en) 2019-11-27 2020-11-25 Combination therapy involving diaryl macrocyclic compounds

Publications (1)

Publication Number Publication Date
BR112022010277A2 true BR112022010277A2 (pt) 2022-10-11

Family

ID=75971599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010277A BR112022010277A2 (pt) 2019-11-27 2020-11-25 Terapia combinada que envolve compostos macrocíclicos de diarila

Country Status (12)

Country Link
US (2) US11666574B2 (pt)
EP (1) EP4065395A4 (pt)
JP (1) JP2023504046A (pt)
KR (1) KR20220134522A (pt)
CN (1) CN114867622A (pt)
AU (1) AU2020391220A1 (pt)
BR (1) BR112022010277A2 (pt)
CA (1) CA3163095A1 (pt)
IL (1) IL293208A (pt)
MX (1) MX2022006366A (pt)
TW (1) TW202133856A (pt)
WO (1) WO2021108672A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901286B (zh) * 2019-11-27 2024-05-10 特普医药公司 涉及二芳基巨环化合物的组合疗法
CN115916346A (zh) * 2020-04-27 2023-04-04 维瑞斯特姆股份有限公司 用于治疗异常细胞生长的方法
IL311158A (en) * 2021-08-30 2024-04-01 Yeda res & development co ltd Combination therapy including MEK and SRC inhibitors for cancer treatment
WO2023108110A2 (en) * 2021-12-10 2023-06-15 Verastem, Inc. Combination therapy for treating abnormal cell growth
WO2023178284A1 (en) * 2022-03-17 2023-09-21 St. Jude Children’S Research Hospital Treatment of low-grade glioma with mirdametinib
US11806322B2 (en) * 2022-03-17 2023-11-07 Springworks Therapeutics, Inc. Mirdametinib treatment
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
ES2735729T3 (es) 2014-01-24 2019-12-20 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteínas cinasas
ES2779975T3 (es) * 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
US10316044B2 (en) 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
BR112018000297A2 (pt) 2015-07-06 2018-09-04 Tp Therapeutics Inc polimorfo de macrociclo de diarila
BR112018001065A2 (pt) 2015-07-21 2018-09-11 Tp Therapeutics, Inc. macrociclos diarila quirais e usos dos mesmos
AU2016370846B2 (en) * 2015-12-18 2022-08-25 Ignyta, Inc. Combinations for the treatment of cancer
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法

Also Published As

Publication number Publication date
AU2020391220A1 (en) 2022-06-30
CN114867622A (zh) 2022-08-05
WO2021108672A1 (en) 2021-06-03
US20230398119A1 (en) 2023-12-14
IL293208A (en) 2022-07-01
EP4065395A4 (en) 2024-02-14
JP2023504046A (ja) 2023-02-01
EP4065395A1 (en) 2022-10-05
US11666574B2 (en) 2023-06-06
CA3163095A1 (en) 2021-06-03
TW202133856A (zh) 2021-09-16
MX2022006366A (es) 2022-06-22
US20210154198A1 (en) 2021-05-27
KR20220134522A (ko) 2022-10-05

Similar Documents

Publication Publication Date Title
BR112022010277A2 (pt) Terapia combinada que envolve compostos macrocíclicos de diarila
BR112021022812A2 (pt) Dosagem de inibidor de kras para tratamento de cânceres
CR20190252A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
MX2020008404A (es) Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
EA201892510A3 (ru) Комбинированная терапия для лечения рака
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
HK1130438A1 (en) Using pi3k and mek modulators in treatments of cancer
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
CL2022001794A1 (es) Terapia combinada que comprende inhibidores de a2a/a2b y pd-1/pd-l1.
AU2019310335A8 (en) Methods of treating cancer with PI3K inhibitor, GDC-0077
BR112018074283A2 (pt) composição e métodos para terapia com microbiota.
CL2013003307A1 (es) Agente que comprende ciazofamida o fenamidona; y su uso para tratar micosis en peces e invertebrados en todos sus estadios de desarrollo causada por hongos de los generos saprolegnia, achlya y aphanomyces (div.sol.n°1056-08).
MX2017004580A (es) Combinaciones de auristatina sinergica.
MX2020003954A (es) Vectores lentivirales para suministro de pklr para el tratamiento de deficiencia de piruvato quinasa.
BR112022010278A2 (pt) Terapia combinada que envolve compostos macrocíclicos de diarila
BR112023015616A2 (pt) Terapia de combinação para tratamento de crescimento celular anormal
CR20190471A (es) Moduladores de la expresión de pcsk9
ECSP23019525A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
CO2021007006A2 (es) Moduladores de la expresión de irf5
BR112019009726A2 (pt) terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica
BR112019008241A2 (pt) tratamento do prurigo nodular
CO2022018016A2 (es) Composiciones y métodos para inhibir la proliferación de células musculares lisas vasculares
BR112022008295A2 (pt) Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer
BR112023022774A2 (pt) Terapias de combinação para tratamento de câncer
BR112019005815A2 (pt) métodos de tratamento de um indivíduo com câncer de mama, kit para o tratamento de câncer de mama e combinação de fármacos para terapia de câncer de mama

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]